Deals With Pfizer, Sanofi-Aventis, AstraZeneca Boost Korea As Clinical Trial Destination
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A string of deals during the past five years with five multinational companies - Pfizer, Sanofi-Aventis, AstraZeneca, Novartis and Japan's Otsuka Pharmaceuticals - have boosted South Korea's status as a leading destination for global clinical trials, according to the government